« (Don't) Trust And (Don't) Verify |
| Grabbing Onto A Protein's Surface »
March 23, 2009
And While We're Talking About Industry-Sponsored Studies. . .
Last week's discussions around here about the merits (and demerits) of pharma-industry research seem to be coming at what's either a really good or a really bad time. Take a look at this Washington Post article on the handling of clinical data at AstraZeneca.
These details have come up during a large array of lawsuits over Seroquel (quetiapine). And if they're as represented in this article, it doesn't make AZ's marketing folks look very good, and (by extension) the rest of the industry's. We shouldn't be doing this sort of thing, on general principle. But if that's not enough, and it probably isn't, here's a more practical concern: does it take much imagination or vision to think that, with all kinds of health care reform ideas in the air, this sort of behavior might just make Congress want to reform our industry really good and hard?
+ TrackBacks (0) | Category: Clinical Trials | Press Coverage | Regulatory Affairs | The Central Nervous System | Why Everyone Loves Us
POST A COMMENT
- RELATED ENTRIES
- A Nobel Follow-Up
- Not What It Says On the Label, Though
- Selective Inhibitor, The Catalog Says
- Standard of Care? Not So Fast, Not in the United Kingdom
- Natural Product Fragments: Get Rid of the Ugly Ones Now
- Phil Baran at Blog Syn
- An Interview
- ENCODE: The Nastiest Dissent I've Seen in Quite Some Time